載入中
NASDAQHealthcareBiotechnology
最新資料
US$259.86
−US$3.69 · -1.40%
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.
前收盤價
US$259.86
−US$3.69 · -1.40%
盤中時間採用ET。市場資料可能有所延遲。
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.
日內區間
目前US$259.86
52週區間
目前US$259.86
盤中時間採用ET。市場資料可能有所延遲。
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.
日內區間
目前US$259.86
52週區間
目前US$259.86
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | 855.3萬 USD | 244.7萬 USD | — | — |
| 銷貨成本 | 14萬 USD | 1.52億 USD | 8676.6萬 USD | 1.54億 USD | — |
| 毛利 | −14萬 USD | −1.44億 USD | −8431.9萬 USD | −1.54億 USD | — |
| 研究與開發 | 2.67億 USD | 1.52億 USD | 8676.6萬 USD | 1.55億 USD | 1.2億 USD |
| 銷售、一般及管理費用 | 5908.3萬 USD | 5630.5萬 USD | 4205.4萬 USD | 5954.6萬 USD | 4707.5萬 USD |
| 營業費用 | 3.26億 USD | 5630.5萬 USD | 4205.4萬 USD | 6054.6萬 USD | 1.67億 USD |
| 利息收入 | 2293萬 USD | 1734.6萬 USD | — | — | — |
| 折舊和攤銷 | 14萬 USD | 35.8萬 USD | 43.2萬 USD | 41.9萬 USD | 18.2萬 USD |
| 營業利益 | −3.26億 USD | −2億 USD | −1.26億 USD | −2.15億 USD | −1.67億 USD |
| 淨利 | −3.03億 USD | −1.83億 USD | −1.23億 USD | −2.14億 USD | −1.67億 USD |
公司資料更新於 2026年10月11日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2023年11月29日 | 1:15 | — | — |
已生效 2023年11月29日
1:15
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI3.11億0.01%2.3兆 USD0.03%US$381.94+0.63%
Vanguard Morningstar Small-Cap ETFVB2.25億0.12%1853億 USD0.03%US$289.48+0.64%
iShares Russell 2000 ETFIWM1.74億0.22%787.4億 USD0.19%US$278.94+0.49%
Vanguard Morningstar Small-Cap Value ETFVBR1.34億0.20%682億 USD0.05%US$234.43+0.22%
State Street SPDR S&P Biotech ETFXBI1.14億1.16%98.74億 USD0.35%US$153.77+3.00%
Vanguard Extended Market ETFVXF1.07億0.11%954億 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO6119.18萬0.44%139.17億 USD0.24%US$356.78+0.94%
iShares Biotechnology ETFIBB5363.08萬0.51%108.2億 USD0.44%US$206.49+3.00%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap Value ETFVBRState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
